Are you ready for fundamental disruption to key account management practice? While the Key Account Management (KAM) role will continue to prioritise the development of long-term, sustainable partnerships between...

Are you fully and efficiently exploiting real-world data across your business? The impact of real-world data (RWD) is growing but few companies are fully exploiting its potential across all clinical and commercial areas...

Can pharma persuade payers of the benefits of indication-level pricing? Advocates argue that indication-level pricing can bring new products on stream and results in wider patient access to new therapies. That's a good...

As the Institute for Clinical and Economic Review's (ICER) influence on payer behaviour and health policy grows, how should pharma respond? The ICER's novel and inclusive work on the value of drugs, using its own value...

The key to commercial success for biosimilars? Find out what the experts say The biosimilars market is in a state of flux as key players in the US and Europe actively seek to improve perceptions, shape the market, and...

Building the most effective strategy for fast track market access Getting to market faster clearly has benefits, but there are also potential downsides for drug companies too. You need to know the options and consider...

The biologics competitive landscape is at a critical stage of development. How will you respond? Biosimilars are on the offensive across Europe and beyond. With the recent launches of multiple new biosimilars to compete...

So what will persuade US payers to better support orphan drugs? US payer concern at the number of new orphan drugs coming to market, often with eye watering prices attached, can obscure a more positive message: payers...